

Table S1

Antibody list

| Anti-human | Conjugation | Source | Catalog number | Clone | Application |
|--------------------------------|-------------|-----------|----------------|-----------------|----------------|
| Anti-human CD45 | Percp | BD | 347464 | 2D1 | flow cytometry |
| Anti-human CD19 | APC | BD | 340437 | SJ25-C1 | flow cytometry |
| Anti-human CD20 | PE | BD | 346595 | L27 | flow cytometry |
| Anti-human CD3 | PE | BD | 347347 | SK7 | flow cytometry |
| Anti-human CD14 | FITC | BD | 347493 | MφP-9 | flow cytometry |
| Anti-human CD16 | FITC | BD | 347523 | NKP15 | flow cytometry |
| Anti-human CD56 | PE | BD | 347747 | MY31 | flow cytometry |
| Anti-human CD34 | PE | BD | 348057 | 8G12 | flow cytometry |
| Anti-ABCG2 | none | Abcam | ab207732 | EPR20080 | WB |
| Anti-Nanog | none | Abcam | ab109250 | EPR2027(2) | WB |
| Anti-OCT4 | none | Abcam | ab19857 | polyclonal | WB |
| Anti-SOX2 | none | Wanlei | WL00982 | polyclonal | WB |
| Mouse Anti-β actin | none | Zsbio | TA-09 | OTI1 | WB |
| Goat Anti-Mouse IgG | HRP | ABclonal | AS003 | polyclonal | WB |
| Goat Anti-Rabbit IgG | HRP | ABclonal | AS014 | polyclonal | WB |
| Anti-human CD45 | none | Maixin | Kit-0024 | PD7/26+2B1 1 | IHC |
| Anti-human CD3 | none | Maixin | Kit-0003 | SP7 | IHC |
| Anti-human CD19 | none | Maixin | MAB-0646 | LE-CD19 | IHC |
| Anti-human MUM1 | none | Maixin | MAB-0573 | MUM1p | IHC |
| Anti-human Bcl-6 | none | Maixin | MAB-0598 | LN22 | IHC |
| Anti-human CD10 | none | Gene Tech | GT200407 | 56C6 | IHC |
| Anti-human CD20 | none | Gene Tech | GM075507 | L26 | IHC |
| Anti-human CD79α | none | Gene Tech | GM705007 | JCB117 | IHC |
| Anti-human Bcl-2 | none | Gene Tech | GM088704 | 124 | IHC |
| Anti-human cyclin-D1 | none | Gene Tech | GT205807 | SP4 | IHC |
| Anti-human ki67 | none | Gene Tech | GT210107 | SP6 | IHC |
| Goat Anti-Mouse/ Rabbit IgG | HRP | Zsbio | PV-6000 | polyclonal | IHC |

Table S2

Primer sequences list.

| Gene | Forward primer5'-3' | Reverse primer5'-3' |
|-------|----------------------------|---------------------------|
| ABCG2 | ACGAACGGATTAACAGGGTCA | CTCCAGACACACCACGGAT |
| Nanog | AATACCTCAGCCT CCAGCAGAT | TGCGTCACACCA TTGCTATTCTTC |
| OCT4 | CTTGCTGCAGAAGTGGGTGGAGGAA | CTGCAGTGTGGGTTTCGGGCA |
| SOX2 | AAATGGGAGGGGTGCAAAAGAG GAG | CAGCTGTCATTTGCTGTGGGTGATG |
| GAPDH | ACCACA GTCCATGC CATCAC | TCC ACCACCCTGTTGCTGTA |

Table S3

Tumor-initiating capacity of limiting dilutions of CD45⁺CD19⁺ and CD45⁺CD19⁻ cells from the LCL and Farage cell lines again.

| Cell | LCL cell line | | Farage cell line | |
|-----------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| | CD45 ⁺ CD19 ⁺ | CD45 ⁺ CD19 ⁻ | CD45 ⁺ CD19 ⁺ | CD45 ⁺ CD19 ⁻ |
| No. of cells injected | Tumors formed | | Tumors formed | |
| 10 ⁶ | 6/6 | 3/6 | 6/6 | 4/6 |
| 5×10 ⁵ | 4/6 | 3/6 | 6/6 | 5/6 |
| 10 ⁵ | 4/6 | 3/6 | 3/6 | 0/6 |




Figure S1. Pathological features of LCL xenotransplantation tumor (×200). They are consistent with the pathological features of diffuse large B cell lymphoma.




Figure S2.

Verify tumorigenicity of CD45⁺CD19⁺ and CD45⁺CD19⁻ cells in LCL and Farage cell line again. (A) the weight of tumors generated by CD45⁺CD19⁺ cells were higher than CD45⁺CD19⁻ cells from the LCL cell line. (B) the weight of tumors generated by CD45⁺CD19⁺ cells were higher than CD45⁺CD19⁻ cells from the Farage cell line. * $p \leq 0.05$, ** $p \leq 0.01$.